7th Annual Spring to Life Conference on Lung Cancer

LIVE Online Event

Albany, NY | October 10, 2020

Proudly Hosted by New York Oncology Hematology, PC
Proudly Hosted by New York Oncology Hematology


  • Earn your CME credits LIVE!
  • Each lecture will be recorded and made available for review
  • Upon registration, confirmation will be provided via email
  • Login information and instructions will be provided prior to the event

Next quote »

"Identification of molecular drivers has resulted in tailored treatments for our patients with non-small cell lung cancer which are not only more effective, but less toxic. It is essential the community oncologist have a keen knowledge of the most current precision testing techniques and incorporate newer therapies to provide state-of-the-art care to patients close to home."

-Makenzi Evangelist, M.D., New York Oncology Hematology

“The landscape of lung cancer with new biomarkers, immunotherapies, and targeted therapies is constantly evolving, and it is a challenge for the community oncologist to integrate and apply this new knowledge in daily clinical practice. Accessible continuing education forums are crucial to support this rapid evolution of cancer care."

-Nischala Ammannagari, M.D., New York Oncology Hematology


Please click here if you would like to be notified when registration is open. We hope to see you in 2020!
S2L | Registration HCP


The focus of the 2020 Spring to Life live online Conference is Lung Cancer. New York Oncology Hematology (NYOH) has identified an ongoing unmet need for medical education in the area of lung cancer. To meet this need, NYOH, in collaboration with The University of Chicago Pritzker School of Medicine, myMedEd, Inc. and a panel of expert faculty from the academic, research, and community practice settings, developed an accredited, multi-supported, ½ -day educational conference. This is the seventh of these annual conferences that include programming for cancer clinicians.


The purpose of this conference is to educate practitioners and update their knowledge of existing and emerging therapies for the management of patients with lung cancer.


The target audience for this conference is medical oncologists, radiation oncologists, surgical oncologists, thoracic surgeons, pulmonologists, radiologists, interventional radiologists, pathologists, oncology nurses, advanced practice providers, family and primary care practitioners, allied health professionals, and any other individuals with an interest in the care of patients with lung cancer.


After completing this activity, participants will be able to:
  • Describe current and evolving management strategies for patients with localized and locally advanced, non-small cell lung cancer.
  • Identify best practices in biomarker testing and the utilization of biomarkers to drive treatment decisions for patients with lung cancer.
  • Explain the application of targeted therapy and immunotherapy in the treatment of NSCLC.
  • Outline the clinical trial data on the use of molecular drivers in the management of patients with advanced, non-small cell lung cancer.
  • Summarize current and emerging strategies in the management of patients with advanced, non-small cell lung cancer without driver mutations.

This Activity Is Planned By myMedEd, Inc.

Educational Partners

Accredited Provider:

Accredited Provider
Educational Partner
Image Image

This Activity Is Planned By myMedEd, Inc.